Catecholamine-Induced Senescence of Endothelial Cells and Bone Marrow Cells Promotes Cardiac Dysfunction in Mice.

Previous studies have suggested that cellular senescence plays a central role in the progression of pathologic changes in the failing heart. It is well known that the sympathetic nervous system is activated in patients with heart failure, and this change is associated with poor clinical outcomes. Sympathetic activation increases the levels of various catecholamines, such as epinephrine and norepinephrine, but the contribution of these catecholamines to cellular senescence associated with heart failure remains to be determined. We found that catecholamine infusion induced senescence of endothelial cells and bone marrow cells, and promoted cardiac dysfunction in mice. In C57BL/6NCr mice, the continuous infusion of isoproterenol-induced cardiac inflammation and cardiac dysfunction. Expression of p53, a master regulator of cellular senescence, was increased in the cardiac tissue and bone marrow cells of these mice. Suppression of cellular senescence by genetic deletion of p53 in endothelial cells or bone marrow cells led to improvement of isoproterenol-induced cardiac dysfunction. In vitro studies showed that adrenergic signaling increased the expression of p53 and adhesion molecules by endothelial cells and macrophages. Our results indicate that catecholamine-induced senescence of endothelial cells and bone marrow cells plays a pivotal role in the progression of heart failure. Suppression of catecholamine-p53 signaling is crucial for inhibition of remodeling in the failing heart.

[1]  T. Minamino,et al.  Physiological and pathological cardiac hypertrophy. , 2016, Journal of molecular and cellular cardiology.

[2]  D. Kuster,et al.  β‐adrenergic receptor signalling and its functional consequences in the diseased heart , 2016, European journal of clinical investigation.

[3]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[4]  T. Kushnir,et al.  Macrophages dictate the progression and manifestation of hypertensive heart disease. , 2016, International journal of cardiology.

[5]  N. Sharpless,et al.  Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.

[6]  H. Tsutsui,et al.  Skeletal Muscle Abnormalities in Heart Failure. , 2015, International heart journal.

[7]  T. Minamino,et al.  p53-Induced inflammation exacerbates cardiac dysfunction during pressure overload. , 2015, Journal of molecular and cellular cardiology.

[8]  T. Minamino,et al.  Pathological role of adipose tissue dysfunction in cardio-metabolic disorders. , 2015, International heart journal.

[9]  E. Braunwald The war against heart failure: the Lancet lecture , 2015, The Lancet.

[10]  M. Kessel,et al.  Endothelial p53 Deletion Improves Angiogenesis and Prevents Cardiac Fibrosis and Heart Failure Induced by Pressure Overload in Mice , 2015, Journal of the American Heart Association.

[11]  T. Minamino,et al.  DNA damage response and metabolic disease. , 2014, Cell metabolism.

[12]  Akiyoshi Uemura,et al.  Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. , 2013, Cell metabolism.

[13]  V. Conti,et al.  Adrenergic signaling and oxidative stress: a role for sirtuins? , 2013, Front. Physiol..

[14]  Torsten Doenst,et al.  Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.

[15]  L. Partridge,et al.  The Hallmarks of Aging , 2013, Cell.

[16]  Daniel G. Anderson,et al.  Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone Mice , 2013, Circulation.

[17]  J. Campisi,et al.  Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.

[18]  A. Boyle,et al.  The aging heart and post-infarction left ventricular remodeling. , 2011, Journal of the American College of Cardiology.

[19]  Masayuki Orimo,et al.  A crucial role for adipose tissue p53 in the regulation of insulin resistance , 2009, Nature Medicine.

[20]  P. Ponikowski,et al.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[21]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[22]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[23]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[24]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[25]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[26]  E. Lakatta,et al.  Cardiovascular regulatory mechanisms in advanced age. , 1993, Physiological reviews.

[27]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[28]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[29]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[30]  吉田 陽子 p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure , 2013 .

[31]  R. Lefkowitz,et al.  β-Adrenergic Receptor Kinase-1 Levels in Catecholamine-Induced Myocardial Hypertrophy Regulation by β- but not α1-Adrenergic Stimulation , 1999 .

[32]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.